ArticleClinical and translational radiation oncology2021
Feasibility of MR-guided ultrahypofractionated radiotherapy in 5, 2 or 1 fractions for prostate cancer.
Article in Clinical and translational radiation oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Optimal timing of the cumulative dose and factors related to acute urinary toxicity in prostate cancer treated using magnetic resonance linear accelerator.Radiological physics and technology · 2026Article
- Article
- Towards clinical implementation of T2-weighted cine imaging for intrafraction drift correction workflows on the 1.5 Tesla magnetic resonance-linear accelerator.Physics and imaging in radiation oncology · 2025Article
- Apparent diffusion coefficient as a quantitative biomarker for prostate cancer treatment response on a 1.5 Tesla magnetic resonance-linear accelerator: Impact of image registration and acquisition type.Physics and imaging in radiation oncology · 2025Article
- Reconstructed dose and geometric coverage for tight margins using intrafraction re-planning on an integrated magnetic resonance imaging and linear accelerator system for prostate cancer patients.Physics and imaging in radiation oncology · 2025Article
- Beginning of clinical treatment using the 1.5 Tesla MR-Linac system in Japan: a narrative review.Translational cancer research · 2024Review
- Evaluation of Unity 1.5 T MR-linac plan quality in patients with prostate cancer.Journal of applied clinical medical physics · 2023Article
- Article
- HERMES: Delivery of a Speedy Prostate Cancer Treatment.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2022Article
- Estimation of secondary cancer projected risk after partial breast irradiation at the 1.5 T MR-linac.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Article
- Integrated MRI-guided radiotherapy - opportunities and challenges.Nature reviews. Clinical oncology · 2022Review
- Article
- [Primary treatment of prostate cancer using 1.5 T MR-linear accelerator].Der Radiologe · 2021Review
- On-line daily plan optimization combined with a virtual couch shift procedure to address intrafraction motion in prostate magnetic resonance guided radiotherapy.Physics and imaging in radiation oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The drive towards hypofractionated prostate radiotherapy is motivated by a low alpha/beta ratio for prostate cancer (1 to 3 Gy) compared to surrounding organs at risk, implying an improved therapeutic ratio with increasing dose per fraction. Early evidence from studies of ultrahypofractionated (UHF) prostate HDR brachytherapy has shown good tolerability in terms of normal tissue toxicities and clinical outcomes similar to conventional fractionation schedules. MR-guided stereotactic body radiotherapy (SBRT) with online plan adaptation and real-time tumour imaging may enable UHF doses to be delivered to the prostate safely, without the invasiveness of brachytherapy. The feasibility of UHF prostate treatment planning for the Unity MR-Linac (MRL, Elekta AB, Stockholm) was investigated for target prescriptions and planning constraints derived from the HDR brachytherapy and SBRT literature. Monaco 5.40 (Elekta) was used to generate MRL step-and-shoot IMRT plans for three dose fractionation protocols (5, 2 and 1 fractions), for ten randomly selected previously treated prostate cancer patients. Of the ten plans per UHF scheme, all clinical goals were met in all cases for 5 fractions, and in six cases for both 2 and 1 fraction schemes. PTV D95% was compromised by up to 6.4% and 3.9% of the associated target dose for 2 and 1 fraction plans respectively. There were two cases of PTV D95% compromise greater than a 5% dose decrease for the 2 fraction plans. The study suggests feasibility of the UHF treatment planning approaches if combined with real-time motion mitigation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.